Opus Genetics, Inc. annual report, FY2018

Filing identity and reporting period

Important mismatch: The request identifies Opus Genetics, Inc., but the supplied Form 10-K is for Rexahn Pharmaceuticals, Inc. It reports the fiscal year ended December 31, 2018, not a standalone 2018 fourth-quarter filing. The summary below reflects the supplied Rexahn filing.

Business context

Rexahn was a clinical-stage oncology biopharmaceutical company with no approved products or product sales. Its principal clinical programs were RX-3117 and RX-5902; RX-0301 was in preclinical development and partnered with Zhejiang Haichang for development in China. The company relied on external collaborators, contract research organizations and manufacturers.

Financial results and liquidity

Operating expenses rose about 18% year over year, chiefly reflecting higher clinical-trial and manufacturing costs. R&D expense increased about 22%, including clinical-trial costs of approximately $5.978 million versus $4.325 million. Net loss narrowed largely because the company recorded a $5.546 million noncash gain on warrant fair value in 2018, compared with a $7.594 million noncash loss in 2017; the operating loss increased. The filing provides no meaningful product gross margin because there were no product revenues.

Total assets were $16.043 million and total liabilities were $5.480 million at December 31, 2018. The balance sheet reports $2.308 million of warrant liabilities; it does not identify conventional borrowings or interest-bearing debt. Year-end stockholders’ equity was $10.563 million. No cash-flow margin is applicable to this pre-revenue company.

Fourth-quarter detail

In the unaudited quarter ended December 31, 2018, Rexahn reported expenses of $4.966 million, operating loss of $4.966 million, net loss of $3.117 million and basic and diluted loss per share of $0.09. In the comparable 2017 quarter, net loss was $3.592 million and loss per share was $0.12.

Material developments, outlook and risks

• RX-3117: The company reported final results from a Phase 2a study in relapsed or refractory pancreatic cancer: 31% of patients had progression-free survival of at least two months, and five patients (12%) had disease stabilization exceeding four months. A separate first-line pancreatic combination study with ABRAXANE reached its target enrollment in February 2019; preliminary January 2019 results were not audited and included a 38% overall response rate among 24 patients evaluable for response. These are early clinical findings, not evidence of approval or established benefit.
• RX-5902: Enrollment in the TNBC monotherapy Phase 2a study stopped in December 2018; the company said the data did not support further monotherapy development. A proposed Phase 2 combination study with Merck’s KEYTRUDA remained uncertain, and Rexahn said it might not proceed.
• RX-0201/RX-0301: Rexahn discontinued its internally funded RX-0201 renal-cell-cancer program in 2018 amid changes in treatment options. Haichang agreed to fund RX-0301 development through a Phase 2a proof-of-concept trial, up to an aggregate $10 million, subject to the collaboration terms.
• Funding and runway: Rexahn raised $7.5 million gross in an October 2018 offering and, after year-end, $8.6 million gross in a January 25, 2019 offering. Management stated that cash, cash equivalents and marketable securities, including the January offering proceeds, were expected to fund current activities for at least 12 months after issuance of the financial statements. The filing also describes prior substantial doubt about going concern in the September 2018 quarterly filing and emphasizes continued dependence on external financing.
• Outlook: Management expected RX-3117 expenses to remain roughly flat in 2019, while RX-5902 and RX-0201 expenses were expected to decline. The company could not estimate total development costs or timing to market; it anticipated ongoing losses and negative operating cash flow.
• Key risks and contingencies: Clinical outcomes and regulatory approvals are uncertain; the company depends on third parties for trials and manufacturing, has no commercial infrastructure, and may need additional capital. At February 11, 2019, it disclosed only about 3,336 authorized common shares available for issuance without further charter action, creating a potential constraint on financing or strategic transactions. Contracted R&D agreements had an estimated $6.340 million remaining cost at year-end. No material litigation was reported.
• Unusual item: Termination of the Next BT collaboration led to recognition of $368,750 as other income; the replacement arrangement includes potential royalties and sharing of certain licensing proceeds, capped at $5 million.

Most important facts for investors to verify

1. Confirm the issuer: the supplied filing is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
2. Review the full audited financial statements and cash-flow detail, especially the $18.839 million operating cash outflow and declining year-end liquidity.
3. Assess financing runway using the January 2019 offering’s net proceeds, subsequent cash burn and any further capital needs; management’s 12-month estimate is conditional.
4. Verify the status and complete results of RX-3117 trials and whether Rexahn proceeds with the proposed RX-5902/KEYTRUDA study.
5. Evaluate dilution and capital-raising capacity, including outstanding warrants/options, the January 2019 offering and the disclosed authorized-share limitation.